# HARMONi-6: ivonescimab plus chemo extends survival over tislelizumab plus chemo in squamous lung cancer

Canonical page: https://technooptimist.io/stories/harmoni-6-ivonescimab-plus-chemo-extends-survival-over-tislelizumab-55af2e13
Date: 31 May 2026
About: [Summit Therapeutics](https://technooptimist.io/companies/summit-therapeutics.md) · [Ivonescimab](https://technooptimist.io/biotech/ivonescimab.md)
Original source: https://www.sec.gov/Archives/edgar/data/0001599298/000159929826000043/ivonescimab-withxchemoth.htm

Akeso's China phase 3 HARMONi-6 showed that ivonescimab plus platinum chemotherapy lengthened survival compared with the PD-1 antibody tislelizumab plus chemotherapy as first treatment for squamous lung cancer. The data were presented at the ASCO 2026 plenary and published in The Lancet. It is the first survival win for a PD-1 x VEGF bispecific against a PD-1 drug in a chemo combination.

## Key facts

- 532 patients; overall survival HR 0.66 (p=0.0017), median 27.9 vs 23.7 months.
- 24-month survival 64.7% vs 48.6%; benefit seen with and without PD-L1 expression.
- Serious treatment-related side effects 41.4% vs 34.3%; grade 3+ bleeding 2.6% vs 0.8%.
- Single-region trial in China, with data generated and analysed by Akeso.

---

The Techno Optimist tracks every frontier of technology, program by program: https://technooptimist.io/ (a Markdown version of any page: add .md to its URL; site map for agents: https://technooptimist.io/llms.txt).
Data API (JSON, realtime stream): https://technooptimist.io/developers. People read 5 pages free, then Reader $10/month; these Markdown pages are open to agents.